What You Should Know:
– GE HealthCare launches CardioVisio for Atrial Fibrillation (AFib), a digital tool designed to assist clinicians in visualizing longitudinal data relevant for disease progression from multiple data sources, and driving evidence based clinical decision support directed by up-to-date AFib guidelines.
– CardioVisio for Atrial Fibrillation is now commercially available in the U.S. GE Healthcare plans to expand availability in the coming months incorporating additional regional guidelines.
CardioVisio for AFib
Cardiovascular diseases are the leading cause of death globally, with more than 60% of these deaths being preventable and premature.[i],[ii] Within the umbrella of cardiovascular disease, AFib is the most common arrhythmia diagnosed in clinical practice, affecting millions of people worldwide – projections indicate that the prevalence of AFib could reach 15.9 million people in the United States by 2050 and 17.9 million in Europe by 2060. Integrating and analyzing data over time and across various data sources, CardioVisio for Atrial Fibrillation helps visualize the history of the patient’s heart and provides guideline-directed insights to healthcare providers. Each automated step includes explainability and traceability, allowing the healthcare provider to audit and edit the process and output with the goal of better meeting the needs of each unique AFib patient.
“Existing diagnosis and treatment care models for AFib have been shown to be complex, time consuming and disconnected with disparate guidelines and poor guideline adherence,” said Eigil Samset, PhD, general manager, Cardiology Solutions, GE HealthCare. “With CardioVisio for AFib, we’re providing cardiologists with a powerful tool to tell the story of the heart, including previous diagnoses, prescribed medications, interventions, and comorbidities.”
